Starling Oncology, Inc., formerly The Oncology Institute, Inc., is advancing oncology by delivering specialized, value-based cancer care in the community setting. The Company offers cutting-edge, evidence-based cancer care to a population of approximately 2.1 million patients, including clinical trials, transfusions, and other care delivery models traditionally associated with oncology organizations. Its critical services include cancer treatment and infusion centers, in-house dispensary, lab testing, outpatient blood transfusion, financial counseling, end-of-life counseling and comprehensive clinical trials. It treats many forms of cancer, including Acute lymphoblastic leukemia; Acute myeloid leukemia; Bladder cancer; Bone cancer; Brain cancer; Cervical cancer; Choriocarcinoma; Chronic lymphocytic leukemia (CLL); Chronic myeloid leukemia (CML); Skin cancer, and others. It operates over 100 clinics and affiliate locations across multiple states.
Back to dashboard
Company Information
About this company
Key people
Anne Mcgeorge
Independent Chairman of the Board
Daniel Virnich
Chief Operating Officer
Brad Hively
Independent Vice Chairman of the Board
Robert Ross Carter
Chief Financial Officer, Principal Accounting Officer
Yale Podnos
Chief Medical Officer
Karen M. Johnson
Independent Director
Mohit Kaushal
Independent Director
Mark L. Pacala
Independent Director
Click to see more
Key facts
- Shares in issue103.65m
- EPICSTLN
- ISINUS68236X1000
- LocationUnited States
- SectorHealthcare
- IndustryHealthcare Facilities
- Market cap$627.80m
- Employees641
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.